BriaCell Therapeutics Corp. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCTX Nasdaq 2834 briacell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BriaCell Therapeutics Corp.

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - May 26th, 2026 5:30 am
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 - May 22nd, 2026 5:30 am
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ - May 15th, 2026 5:30 am
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies - May 14th, 2026 6:45 am
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer - May 14th, 2026 5:30 am
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - May 13th, 2026 5:30 am
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients - May 12th, 2026 5:30 am
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - May 7th, 2026 5:30 am
BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study - May 6th, 2026 5:56 am
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer - May 6th, 2026 5:30 am
BriaCell Announces Six Clinical Data Presentations at ASCO 2026 - Apr 27th, 2026 5:30 am
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models - Apr 21st, 2026 5:30 am
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Apr 20th, 2026 5:30 am
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License - Mar 31st, 2026 2:05 pm
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference - Mar 18th, 2026 5:30 am
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting - Mar 10th, 2026 5:30 am
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - Mar 5th, 2026 2:04 pm
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - Feb 18th, 2026 3:30 pm
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation - Jan 28th, 2026 5:30 am
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients - Jan 27th, 2026 5:30 am